The Risk Evaluation and Mitigation Strategy piece of the FDA Amendments Act of 2007 , aka REMS, was a hot topic at the Task Force meeting last month. While it seems there may be a few wrinkles to work out, our columnist Stephen Lewis thinks it might end up being an area of opportunity for CME providers; others I spoke with weren't so sure we could get past some of the potential conflicts they could involve. Here's a YouTube video he posted recently about REMS:

What do you think? Are the issues insurmountable, or will REMS become part of the CME provider repertoire?

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.